Ricevi le ultime notizie sulle azioni AIM ImmunoTech con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di AIM

Ultime notizie per

AIM ImmunoTech

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

AIM ImmunoTech Inc

AI / ML INNOVATIONS INC by AI / ML Innovations Inc.

AI/ML Innovations Inc

AIMRITE HOLDINGS CORP by Aimrite Holdings Corporation

Aimrite Holdings Corp

Ainos Inc

Aimia Inc

Aimfinity Investment Corp I Units (1 Ord Class A , 1 Class 1 War & 1/2 Class 2 War

Aimfinity Investment Corp I Warrants - Class 1 (21/04/2027)

Aimfinity Investment Corp I Unit (1CL A & 1/2 WT CL 2)

AIMFINITY INV CP I SUBUNT by Aimfinity Investment Corp. I

Aimfinity Investment Corp I

AIMFINITY INV CORP I UTS by Aimfinity Investment Corp. I

News

IPOs

Press Releases

AIM ImmunoTech Announces Closing of $8.0 Million Public Offering

Health Care

General

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Earnings

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025

Management

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Analyst Ratings

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth

Legal

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

AKTX

AMIX

CNSP

MBRX

NUWE

NVNO

SNTI

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Alzamend Neuro

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

enGene Holdings

Ensysce Biosciences

Entero Therapeutics

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals

Galecto

Genprex

GRI Bio

HCW Biologics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Mainz Biomed

Oragenics

Onconetix

Polyrizon

PharmaCyte Biotech

Protagenic Therapeutics, Inc. - Common Stock

Comments

AIM ImmunoTech Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO